secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bluejay Diagnostics, Inc. (BJDX)
CIK:        0001704287
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001213900-26-026749
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bluejay announces Symphony IL-6 Test abstract accepted for SAEM 2026 meeting
----------------------------------------------------------------------------

- Abstract accepted for presentation at Society of Academic Emergency Medicine Annual Meeting, May 18-21, 2026 in Atlanta.
- Presentation reports SYMON-I pilot study data: IL-6 levels in ED linked to organ dysfunction (SOFA scores) in sepsis patients.
- Principal investigator Nathan Shapiro: IL-6 measured in ED may be associated with subsequent organ dysfunction.
- Ongoing SYMON-II pivotal study to validate IL-6 as prognostic biomarker for mortality, to support FDA 510(k) submission.
- Company developing rapid near-patient Symphony IL-6 Test for sepsis triage and monitoring.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704287/000121390026026749/0001213900-26-026749-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704287/000121390026026749/ea0281367-8k_bluejay.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-026749

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer